The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health
出版年份 2014 全文链接
标题
The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health
作者
关键词
-
出版物
PLoS One
Volume 9, Issue 8, Pages e106221
出版商
Public Library of Science (PLoS)
发表日期
2014-08-30
DOI
10.1371/journal.pone.0106221
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study
- (2013) Aoife G. Cotter et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents
- (2012) Roger Bedimo et al. AIDS
- Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
- (2012) Emanuele Focà et al. BMC INFECTIOUS DISEASES
- A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results
- (2012) Michael J. Kozal et al. HIV CLINICAL TRIALS
- Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)
- (2011) Babafemi Taiwo et al. AIDS
- Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results
- (2011) Jacques Reynes et al. HIV CLINICAL TRIALS
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
- (2011) Grace A. McComsey et al. JOURNAL OF INFECTIOUS DISEASES
- A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206
- (2010) Marisa Tungsiripat et al. AIDS
- Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study
- (2010) Hans‐Jürgen Stellbrink et al. CLINICAL INFECTIOUS DISEASES
- Reduced bone mineral density in HIV-infected patients: prevalence and associated factors
- (2009) Charles Cazanave et al. AIDS
- Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week Trial
- (2009) Allison Martin et al. CLINICAL INFECTIOUS DISEASES
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
- (2009) Jeffrey L Lennox et al. LANCET
- Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
- (2009) Paul E. Sax et al. NEW ENGLAND JOURNAL OF MEDICINE
- Class-Sparing Regimens for Initial Treatment of HIV-1 Infection
- (2008) Sharon A. Riddler et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now